CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 301–400 of 1,000
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 46
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 45
Trujillo, J. M., & Nuffer, W. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1903 · Cited by 42
Efficacy of Fasting in Type 1 and Type 2 Diabetes Mellitus: A Narrative Review
Herz, D., Haupt, S., Zimmer, R. T., Wachsmuth, N. B., Schierbauer, J., Zimmermann, P., Voit, T., Thurm, U., Khoramipour, K., RILSTONE, S. K., et al. (2023) · Nutrients · doi:10.3390/nu15163525 · Cited by 45
Henry, R. R., Dandona, P., Pettus, J., Mudaliar, S., Xu, J., & Hansen, L. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12882 · Cited by 42
Wensveen, F. M., Šestan, M., Wensveen, T. T., & Polić, B. (2019) · European Journal of Immunology · doi:10.1002/eji.201847895 · Cited by 47
Myocardial Energy Metabolism in Non-ischemic Cardiomyopathy
Greenwell, A. A., Gopal, K., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.570421 · Cited by 43
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
Kalra, S., Jain, A., Ved, J., & Unnikrishnan, A. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.183826 · Cited by 44
Hupfeld, C., & Mudaliar, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13740 · Cited by 41
“Studies are in progress to study these hypotheses.(46,47) TABLE 4 Major adverse cardiovascular events in the cardiovascular outcome trials with SGLT-2 inhibitors”
BackgroundEmpagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model
Winzer, E. B., Schauer, A., Langner, E., Augstein, A., Goto, K., Männel, A., Barthel, P., Jannasch, A., Labeit, S., Mangner, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231910989 · Cited by 43
Peters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0924 · Cited by 44
Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats
Seefeldt, J. M., Lassen, T. R., Hjortbak, M. V., Jespersen, N. R., Kvist, F., Hansen, J., & Bøtker, H. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-89149-9 · Cited by 42
Avgerinos, K. I., Mullins, R. J., Vreones, M. P., Mustapić, M., Chen, Q., Melvin, D. L., Kapogiannis, D., & Egan, J. M. (2022) · Cells · doi:10.3390/cells11213372 · Cited by 42
Cummings, D. E., & Rubino, F. (2016) · Diabetes Care · doi:10.2337/dci16-0031 · Cited by 42
Jundishapur Journal of Chronic Disease Care
(2026) · Jundishapur Journal of Chronic Disease Care · doi:10.5812/jjcdc · Cited by 41
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
Sarafidis, P. A., Lazaridis, A. A., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.209 · Cited by 41
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
“75 In light of the profound reduction in heart failure hospitalizations with empagliflozin in EMPA-REG, Ferrannini and DeFronzo 76 have hypothesized another novel pathway.”
Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes
Bletsa, E., Filippas-Ntekouan, S., Kostara, C. E., Dafopoulos, P., Dimou, A. D., Pappa, E. T., Chasapi, S. A., Spyroulias, G. A., Koutsovasilis, A., Bairaktari, E. T., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab086 · Cited by 45
Self-citationThe cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects
Vettor, R., Inzucchi, S. E., & Fioretto, P. (2017) · Diabetologia · doi:10.1007/s00125-016-4194-y · Cited by 42
SGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 44
Biester, T., Aschemeier, B., Fath, M., Frey, M., Scheerer, M. F., Kordonouri, O., & Danne, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12975 · Cited by 38
SGLT2 inhibition to address the unmet needs in diabetic nephropathy
Barutta, F., Bernardi, S., Gargiulo, G., Durazzo, M., & Gruden, G. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3171 · Cited by 48
Vasquez‐Rios, G., & Nadkarni, G. N. (2020) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s268811 · Cited by 44
Trnovská, J., Svoboda, P., Pelantová, H., Kuzma, M., Kratochvílová, H., Kasperová, B. J., Pleyerová, I., ROSOLOVÁ, K., Malínská, H., Hüttl, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910606 · Cited by 41
Ketogenic Diet and Cardiac Substrate Metabolism
Luong, T. V., Abild, C. B., Bangshaab, M., Gormsen, L. C., & Søndergaard, E. (2022) · Nutrients · doi:10.3390/nu14071322 · Cited by 41
Bays, H. E., Sartipy, P., Xu, J. L., Sjöström, C. D., & Underberg, J. A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.018 · Cited by 40
Hundertmark, M., Agbaje, O. F., Coleman, R. L., George, J. T., Grempler, R., Holman, R. R., Lamlum, H., Lee, J., Milton, J. E., Niessen, H. G., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13406 · Cited by 39
Zhang, X., Wang, N., Fu, P., An, Y., Sun, F., Wang, C., Han, X., Zhang, Y., Yu, X., & Liu, Y. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001474 · Cited by 37
“8 Ketone bodies, including b -OHB, acetoacetate, and acetone, are mainly produced in the liver of mammals.”
BackgroundGallwitz, B. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.1.17 · Cited by 37
Liu, H., Sridhar, V. S., Montemayor, D., Lovblom, L. E., Lytvyn, Y., Ye, H., Kim, J., Ali, M. T., Scarr, D., Lawler, P. R., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14489 · Cited by 36
Selvaraj, S., Patel, S., Sauer, A. J., McGarrah, R. W., Jones, P. G., Kwee, L. C., Windsor, S. L., Ilkayeva, O., Muehlbauer, M. J., Newgard, C. B., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011980 · Cited by 37
“10,11 The "thrifty substrate" hypothesis further speculates that the mild increase in ketones during SGLT2i therapy may explain benefits observed in HF. 12 Notably, fuel transition in metabolism both at the cardiac and systemic levels is fundamental to HF pathobiology.”
InfluentialNakamura, I., Maegawa, H., Tobe, K., Tabuchi, H., & Uno, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1408792 · Cited by 37
Assaly, R., Gorny, D., Compagnie, S., Mayoux, E., Bernabé, J., Alexandre, L., Giuliano, F., & Behr‐Roussel, D. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.07.002 · Cited by 36
Self-citationAbdurrachim, D., Woo, C. C., Teo, X. Q., Chan, W. X., Radda, G. K., & Lee, P. T. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-39378-w · Cited by 35
Bonora, B. M., de Kreutzenberg, S. V., Avogaro, A., & Fadini, G. P. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0910-5 · Cited by 36
Disruption of energy utilization in diabetic cardiomyopathy; a mini review
Nirengi, S., da Silva, C. P. V., & Stanford, K. I. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.015 · Cited by 36
Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review
Mollace, V., Rosano, G. M. C., Anker, S. D., Coats, A. J. S., Seferovic, P. M., Mollace, R., Tavernese, A., Gliozzi, M., Musolino, V., Carresi, C., et al. (2021) · Nutrients · doi:10.3390/nu13010257 · Cited by 37
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 37
Otsuka, H., Yokomizo, H., Nakamura, S., Izumi, Y., Takahashi, M., Obara, S., Nakao, M., Ikeda, Y., Sato, N., Sakamoto, R., et al. (2022) · Biochemical Journal · doi:10.1042/bcj20210700 · Cited by 38
“Negative energy balance and reduced blood insulin level during SGLT2 inhibition should induce a variety of catabolic responses outside the skeletal muscles, such as adipose tissue lipolysis, which could contribute to the increased production of FFA and ketone bodies [40].”
Osto, E., Bonacina, F., Pirillo, A., & Norata, G. D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106667 · Cited by 40
Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
Yanai, H., Hakoshima, M., Adachi, H., & Katsuyama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094416 · Cited by 35
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
Fan, Z.-G., Xu, Y., Chen, X., Ji, M.-Y., & Ma, G. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s371506 · Cited by 34
Deschaine, B., Verma, S., & Rayatzadeh, H. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.11 · Cited by 37
Omori, K., Katakami, N., Yamamoto, Y., Ninomiya, H., Takahara, M., Matsuoka, T., Bamba, T., Fukusaki, E., & Shimomura, I. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.42945 · Cited by 34
Scholtes, R. A., van Baar, M. J. B., Lytvyn, Y., Bjornstad, P., Nieuwdorp, M., Cherney, D. Z. I., & van Raalte, D. H. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13692 · Cited by 35
The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD + Therapy in HFpEF
Koay, Y. C., McIntosh, B., Ng, Y. H., Cao, Y., Wang, X., Han, Y., Tomita, S., Bai, Y., Hunter, B., Misra, A., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325550 · Cited by 34
Chacko, B., Whitley, M., Beckmann, U., Murray, K., & Rowley, M. (2018) · Anaesthesia and Intensive Care · doi:10.1177/0310057x1804600212 · Cited by 32
Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
Jeon, J. Y., Kim, S.-K., Kim, K.-S., Song, S. O., Yun, J., Kim, B.-Y., Kim, C.-H., Park, S. O., Hong, S., Seo, D. H., et al. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.001 · Cited by 34
Ma, X., Dong, Z., Liu, J., Ma, L., Sun, X., Gao, R., Pan, L., Zhang, J., Dilan, A., An, J., et al. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07267-y · Cited by 37
Hanke, J., Romejko, K., & Niemczyk, S. (2025) · Molecules · doi:10.3390/molecules30204125 · Cited by 35
“Additionally, by reducing oxidative stress and ROS production, preserving mitochondrial integrity, and elevating β OHB levels, SGLT2 inhibitors can stabilize the cell/membrane potential and exert an antiarrhythmic effect [63,64].”
InfluentialBonaventura, A., Carbone, S., Dixon, D. L., Abbate, A., & Montecucco, F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12890 · Cited by 36
Lim, L., Lau, E. S. H., Fung, E., Lee, H. M., Ronald, C. W., Tam, C. H. T., Wong, W. K. K., Ng, A. C. W., Chow, E., Luk, A. O. Y., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3253 · Cited by 45
“In a Mendelian randomization study involving individuals of European ancestry, variants at the PPM1K gene that encode the mitochondrial phosphatase 2c (PP2Cm) necessary for BCKDH activation were strongly associated with increased circulating levels of BCAAs and risk of T2D.2 However, the weighted genetic risk score on…”
BackgroundInfluentialLan, N. S. R., Yeap, B. B., Fegan, P. G., Green, G., Rankin, J. M., & Dwivedi, G. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-02034-w · Cited by 32
The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy
Gopal, K., Chahade, J. J., Kim, R., & Ussher, J. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.603247 · Cited by 36
“Postulated mechanisms for the improvement in diastolic function following treatment with empagliflozin in experimental T2DM include potential increases in myocardial ketone metabolism, as use of SGLT2 inhibitors leads to increases in circulating ketones, which are a more efficient fuel than fatty acids (Ferrannini et…”
BackgroundLyu, Y. S., Oh, S. K., Kim, J. H., Kim, S. Y., & Jeong, M. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01914-4 · Cited by 36
“This metabolic shift can improve energy efficiency, preserve myocardial function, and enhance overall cardiac performance in individuals with HF [56, 57].”
BackgroundChase, D., Eykyn, T. R., Shattock, M. J., & Chung, Y. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad157 · Cited by 33
“14 This could occur (i) indirectly by increasing circulating ketone levels and/or (ii) directly by altering myocardial substrate preference independent of substrate supply.”
BackgroundKashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 33
Wolf, P. S., Fellinger, P., Pfleger, L., Beiglböck, H., Krumpolec, P., Barbieri, C., Gastaldelli, A., Harreiter, J., Metz, M., Scherer, T., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1983 · Cited by 32
The Metabolic Role of GRK2 in Insulin Resistance and Associated Conditions
Sorriento, D., Rusciano, M. R., Visco, V., Fiordelisi, A., Cerasuolo, F. A., Poggio, P., Ciccarelli, M., & Iaccarino, G. (2021) · Cells · doi:10.3390/cells10010167 · Cited by 35
Østergaard, M. V., Secher, T., Christensen, M. S., Salinas, C. G., Roostalu, U., Skytte, J. L., Rune, I., Hansen, H. H., Jelsing, J., Vrang, N., et al. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00154.2021 · Cited by 33
Bechlioulis, A., Markozannes, G., Chionidi, I., Liberopoulos, E. N., Naka, K. Κ., Ntzani, E., Liatis, S., Rizzo, M., & Rizos, E. C. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108436 · Cited by 33
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?
Daou, D., Tong, D., Schiattarella, G. G., Gillette, T. G., & Hill, J. A. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.009 · Cited by 37
Pereira, M. J., Lundkvist, P., Kamble, P. G., Lau, J., Martins, J. G., Sjöström, C. D., Schnecke, V., Walentinsson, A., JOHNSSON, E. K., & Eriksson, J. W. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0449-6 · Cited by 32
Deerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Man, N. H., Suastika, K., Khoo, C. M., Yoon, K., Luk, A. O. Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13819 · Cited by 31
Carreau, A., Noll, C., Blondin, D. P., Frisch, F., Nadeau, M., Pelletier, M., Phoenix, S., Cunnane, S. C., Guérin, B., Turcotte, É. E., et al. (2020) · Diabetes · doi:10.2337/db19-0773 · Cited by 32
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 31
“261,262 SGLT-2 inhibitor is a unique class of antidiabetic agent for diabetic patients with HF.”
Juszczyk, A., Jankowska, K., Zawiślak, B., Surdacki, A., & Chyrchel, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092681 · Cited by 32
Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
Gronda, E., Lopaschuk, G. D., Arduini, A., Santoro, A., Benincasa, G., Palazzuoli, A., Gabrielli, D., & Napoli, C. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0399 · Cited by 31
Yang, T., & Zhang, D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101884 · Cited by 30
Davies, M. J., Merton, K., Vijapurkar, U., Yee, J., & Qiu, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0517-7 · Cited by 32
Yoshida, A., Matsubayashi, Y., Nojima, T., Suganami, H., Abe, T., Ishizawa, M., Fujihara, K., Tanaka, S., Kaku, K., & Sone, H. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02254 · Cited by 31
Yang, D.-Y. D., He, X., Liang, H., Zhang, S., Zhong, X., Luo, C., Du, Z., He, J., Zhuang, X., & Liao, X. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0853-x · Cited by 35
SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation
Schmidt, K., Schmidt, A., Groß, S., Just, A., Pfanne, A., Fuchs, M., Jordan, M., Mohr, E., Pich, A., Fiedler, J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65410-9 · Cited by 33
“This would reflect clinical data showing a reduced utilization of glucose as energy source which, as initially introduced, is being speculated to mediate cardioprotective functions of SGLT2is to a certain degree 12–15 .”
BackgroundThewjitcharoen, Y., Yenseung, N., Malidaeng, A., Nakasatien, S., Chotwanvirat, P., Krittiyawong, S., Wanothayaroj, E., & Himathongkam, T. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0297-y · Cited by 33
Abdurrachim, D., Teo, X. Q., Woo, C. C., Ong, S. Y., Salleh, N. F., Lalic, J., Tan, R., & Lee, P. T. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13608 · Cited by 31
Sodium-glucose cotransporter inhibitors in type 2 diabetes: thinking beyond glucose lowering
Neuen, B. L., Cherney, D. Z. I., Jardine, M., & Perkovic, V. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.190047 · Cited by 32
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
Chen, L., Ma, S., Hu, D., Lin, H., Zhu, Y., Chen, K., Chen, L., Zheng, C., Liu, J., & Liao, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.561494 · Cited by 29
“Furthermore, recent studies have indicated that SGLT2 inhibitors enhance cardiac systolic function by improving myocardial energy production by directing myocardial fuel metabolism away from glucose synthesis toward ketone body (KB) formation (Ferrannini et al., 2016; Santos-Gallego et al., 2019).”
BackgroundContemporary Management of Heart Failure in Patients With Diabetes
Shaw, J., & Cooper, M. (2020) · Diabetes Care · doi:10.2337/dc20-2173 · Cited by 22
Albiero, M., Tedesco, S., Amendolagine, F. I., D’Anna, M., Migliozzi, L., Zuccolotto, G., Rosato, A., Cappellari, R., Avogaro, A., & Fadini, G. P. (2021) · Diabetes · doi:10.2337/db20-1045 · Cited by 29
Jacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 34
Berndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33
Takada, S., Sabe, H., & Kinugawa, S. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2021 · Cited by 31
Kubota, Y., & Shimizu, W. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.03.009 · Cited by 37
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
The Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
“It has been hypothesized that the oxidation of ketone bodies serves as an additional fuel source, which is highly energy-efficient [152] and efficiently extracted by the heart [9,10,153].”
BackgroundMakrecka‐Kuka, M., Korzh, S., Ozola, M., Vilks, K., Cirule, H., Kuka, J., Dambrova, M., & Liepinsh, E. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06989-9 · Cited by 32
Roles of non-coding RNA in diabetic cardiomyopathy
Yao, X., Huang, X., Chen, J., Lin, W., & Tian, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02252-9 · Cited by 28
Peacock, S. C., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002377 · Cited by 30
Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
Sayour, A. A., Ruppert, M., Oláh, A., Benke, K., Barta, B. A., Zsáry, E., Merkely, B. P., & Radovits, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189852 · Cited by 29
Verma, S., Mudaliar, S. R., & Greasley, P. J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02652-5 · Cited by 30
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors
Ito, M., & Tanaka, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.9842-17 · Cited by 30
Carretero‐Gómez, J., Arévalo‐Lorido, J. C., Gómez‐Huelgas, R., de Lucas, M. D. G., Polo, L. M., Aguilar, J. M. V., Ripoll, J. M. S., & Ena, J. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.09.001 · Cited by 30
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
Budoff, M. J., & Wilding, J. P. H. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12948 · Cited by 30
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
Valero‐Muñoz, M., Saw, E. L., Hekman, R. M., Blum, B. C., Hourani, Z., Granzier, H. L. M., Emili, A., & Sam, F. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.966968 · Cited by 32
Renoprotective Effects of SGLT2 Inhibitors
Vallon, V. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.005 · Cited by 33
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
Tschöpe, C., Linthout, S. V., & Kherad, B. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0874-6 · Cited by 27
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.